Sullivan Megan M, Diaz Menindez Maximiliano, Baig Hassan, Irani Anushka, Butendieck Ronald, Wang Benjamin, Berianu Florentina, Mead-Harvey Carolyn, Abril Andy, Majithia Vikas
Department of Internal Medicine, Division of Rheumatology, Mayo Clinic, Scottsdale, AZ 85259, USA.
Department of Internal Medicine, Scottsdale, AZ 85259, USA.
Diagnostics (Basel). 2024 Dec 31;15(1):74. doi: 10.3390/diagnostics15010074.
Pulmonary involvement is commonly observed in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), presenting with manifestations such as diffuse alveolar hemorrhage, inflammatory infiltrates, pulmonary nodules, and tracheobronchial disease. We aimed to identify distinct subgroups of tracheobronchial disease patterns in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) using latent class analysis (LCA), and to evaluate their clinical characteristics and outcomes. We conducted a retrospective cohort study using electronic medical records of patients aged >18 years diagnosed with AAV and tracheobronchial disease between 1 January 2002 and 6 September 2022. Patients with follow-up <6 months were excluded. LCA was employed to identify disease subtypes based on 10 pre-defined indicators. Maximum likelihood estimation with 10 repetitions per model ensured robustness in model selection, guided by the Akaike information criterion (AIC). Patient and disease characteristics were summarized and compared across predicted classes. Statistical analyses included Kruskal-Wallis and Fisher's exact tests for continuous and categorical variables, respectively. The primary outcome was time to relapse of the tracheobronchial inflammation after starting immunosuppressive medication, analyzed using the Kaplan-Meier method and log-rank tests. Secondary outcomes included severity of pulmonary disease on pulmonary function tests, endoscopic interventions, tracheostomy, or mortality during follow-up. Among 136 identified AAV patients assessed for tracheobronchial involvement, 111 (81.6%) were included after excluding 25 without tracheal or bronchial disease. Predominant findings included subglottic stenosis (91.0%), lower tracheal stenosis (16.2%), and bronchial stenosis (17.1%). LCA identified a three-class model as optimal: tracheal predominant ( = 94), tracheobronchial (n = 12), and bronchial predominant (n = 5). Tracheal predominant patients showed reduced risk of ear, eye, and lower respiratory manifestations, with milder obstruction on pulmonary function testing (PFT). Tracheobronchial-class patients were prone to saddle nose deformity (50%), extensive lower respiratory involvement (91.7%), and renal disease (66.7%). Bronchial predominant patients exhibited severe obstructive disease (median forced expiratory volume in 1 s (FEV1)% predicted: 58, IQR 34-66; FEV1/forced vital capacity (FVC) ratio: 56.9, interquartile range (IQR) 43-63.3) but lacked systemic AAV manifestations. LCA classes did not predict outcomes such as endoscopic intervention, tracheostomy, recurrent tracheobronchial narrowing, or mortality. LCA shows promise in subtype stratification of AAV patients, yet its utility in predicting outcomes and guiding treatment remains limited based on our analysis. Future studies with enhanced phenotypic data and larger cohorts are warranted to improve predictive accuracy.
肺部受累在抗中性粒细胞胞浆抗体(ANCA)相关血管炎(AAV)中较为常见,表现为弥漫性肺泡出血、炎症浸润、肺结节和气管支气管疾病等。我们旨在通过潜在类别分析(LCA)确定抗中性粒细胞胞浆抗体(ANCA)相关血管炎(AAV)患者气管支气管疾病模式的不同亚组,并评估其临床特征和预后。我们进行了一项回顾性队列研究,使用2002年1月1日至2022年9月6日期间诊断为AAV和气管支气管疾病的18岁以上患者的电子病历。随访时间<6个月的患者被排除。LCA用于根据10个预先定义的指标识别疾病亚型。每个模型进行10次重复的最大似然估计,以赤池信息准则(AIC)为指导确保模型选择的稳健性。总结并比较预测类别中的患者和疾病特征。统计分析分别包括对连续变量和分类变量的Kruskal-Wallis检验和Fisher精确检验。主要结局是开始免疫抑制治疗后气管支气管炎症复发的时间,采用Kaplan-Meier法和对数秩检验进行分析。次要结局包括肺功能测试中肺部疾病的严重程度、内镜干预、气管切开术或随访期间的死亡率。在136例确定评估气管支气管受累的AAV患者中,排除25例无气管或支气管疾病的患者后,纳入111例(81.6%)。主要发现包括声门下狭窄(91.0%)、气管下段狭窄(16.2%)和支气管狭窄(17.1%)。LCA确定一个三类模型为最佳:气管为主型(n = 94)、气管支气管型(n = 12)和支气管为主型(n = 5)。气管为主型患者耳部、眼部和下呼吸道表现的风险降低,肺功能测试(PFT)中的阻塞较轻。气管支气管型患者易出现鞍鼻畸形(50%)、广泛的下呼吸道受累(91.7%)和肾脏疾病(66.7%)。支气管为主型患者表现出严重的阻塞性疾病(1秒用力呼气容积(FEV1)预测值中位数:58,四分位数间距(IQR)34 - 66;FEV1/用力肺活量(FVC)比值:56.9,四分位数间距(IQR)43 - 63.3),但缺乏系统性AAV表现。LCA类别不能预测内镜干预、气管切开术、复发性气管支气管狭窄或死亡率等结局。LCA在AAV患者的亚型分层中显示出前景,但根据我们的分析,其在预测结局和指导治疗方面的效用仍然有限。需要进一步开展具有增强表型数据和更大队列的研究,以提高预测准确性。